OBLIMERSEN Drug Record

  • OBLIMERSEN chembl:CHEMBL2108324 Antineoplastic

    Alternate Names:

    OBLIMERSEN

    Drug Info:

    FDA Approval not approved
    Drug Class antisense oligo
    Drug Indications antineoplastic agent
    (0 More Sources)

    Publications:

  • OBLIMERSEN   BCL2

    Interaction Score: 4.31

    Interaction Types & Directionality:
    antisense oligonucleotide (inhibitory)

    Interaction Info:
    Trial Name Genasense
    Novel drug target Established target
    Notes

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial TTD

  • TdgClinicalTrial: OBLIMERSEN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class antisense oligo
    FDA Approval not approved

    Publications:

  • TALC: OBLIMERSEN

    • Version: 12-May-2016

    Alternate Names:
    OBLIMERSEN Primary Drug Name
    OBLIMERSEN Drug Generic Name
    GENASENSE Drug Trade Name

    Drug Info:

    Publications:

  • TTD: Oblimersen

    • Version: 2020.06.01

    Alternate Names:
    D05RJP TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL2108324

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications: